XML 45 R33.htm IDEA: XBRL DOCUMENT v3.23.1
FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)
 3 Months Ended
Mar. 31, 2023
Fair Value Disclosures [Abstract]  
Fair value, assets measured on recurring basis
                    
   Fair Value Measurement at March 31, 2023 
   Total   Level 1   Level 2   Level 3 
Assets:                
Investment in common stock of Alzamend Neuro, Inc. (“Alzamend”) – a related party  $4,856,000   $4,856,000   $-   $- 
Investments in marketable equity securities   1,367,000    1,367,000    -    - 
Cash and marketable securities held in trust account   119,254,000    119,254,000    -    - 
Total assets measured at fair value  $125,477,000   $125,477,000   $-   $- 
                     
Liabilities:                    
Series E, F and G preferred stock liabilities  $8,500,000   $-   $-   $8,500,000 
Convertible promissory notes   15,283,000    -    -    15,283,000 
Total liabilities measured at fair value  $23,783,000   $-   $-   $23,783,000 

 

   Fair Value Measurement at December 31, 2022 
    Total    Level 1    Level 2    Level 3 
Assets:                    
Investment in common stock of Alzamend – a related party  $6,449,000   $6,449,000   $-   $- 
Investments in marketable equity securities   6,590,000    6,590,000    -    - 
Cash and marketable securities held in trust account   118,193,000    118,193,000    -    - 
Investments in other equity securities   13,340,000    -    -    13,340,000 
Total assets measured at fair value  $144,572,000   $131,232,000   $-   $13,340,000 
                     
Liabilities:                    
Convertible promissory notes  $12,776,000   $-   $-   $12,776,000 
Schedule of investments
     
   Investments in
other equity
securities
 Balance at January 1, 2023  $ 13,340,000
 Conversion to Level 1 marketable securities    (13,340,000)
 Balance at March 31, 2023  $ -